Rohto Pharmaceutical Co.,Ltd.
4527.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | ¥509 | ¥685 | ¥632 | ¥421 |
| - Cash | ¥77 | ¥89 | ¥80 | ¥73 |
| + Debt | ¥50 | ¥10 | ¥12 | ¥21 |
| Enterprise Value | ¥483 | ¥607 | ¥564 | ¥370 |
| Revenue | ¥309 | ¥271 | ¥239 | ¥200 |
| % Growth | 14% | 13.5% | 19.5% | – |
| Gross Profit | ¥169 | ¥157 | ¥137 | ¥116 |
| % Margin | 54.9% | 58.1% | 57.6% | 58.3% |
| EBITDA | ¥56 | ¥50 | ¥42 | ¥36 |
| % Margin | 18.3% | 18.6% | 17.7% | 17.9% |
| Net Income | ¥31 | ¥31 | ¥26 | ¥21 |
| % Margin | 10% | 11.4% | 11.1% | 10.6% |
| EPS Diluted | 135.46 | 135.21 | 115.29 | 92.34 |
| % Growth | 0.2% | 17.3% | 24.9% | – |
| Operating Cash Flow | ¥37 | ¥34 | ¥31 | ¥27 |
| Capital Expenditures | -¥9 | -¥9 | -¥10 | -¥11 |
| Free Cash Flow | ¥28 | ¥25 | ¥21 | ¥16 |